5 Beauty & Cosmetics Stocks to Buy for a Stable Portfolio in 2H 2026

Zacks screens five Beauty & Cosmetics stocks for a favorable Zacks Rank to buy for 2H 2026: Estée Lauder (Zacks #1), Helen of Troy, Nu Skin, Kenvue, and Interparfums (all #2). The article highlights EL’s expected FY2027 revenue growth of 3.7% and earnings growth of 31.9%, plus a 4.3% improvement in the earnings consensus over the last 60 days, while also citing steady estimate momentum for Kenvue (+5.5% consensus earnings). Overall, it’s a constructive, fundamentally driven sector/stock outlook with no explicit single-catalyst event stated.

Analysis

The cleanest way to express this setup is dispersion, not a blanket long on beauty. The winners are the names with real channel leverage and pricing power: EL has the best operating leverage if omni-channel mix improves, while IPAR benefits from luxury fragrance scarcity and travel retail elasticity, which tends to hold up better than mass beauty in soft consumer tape. KVUE is more of a defensive cash-flow beneficiary than a growth story; it can out-earn its multiple if recession odds rise, but the upside is mostly multiple support.

The weakest link is NUS: when a premium direct-selling model meets flat/negative top-line momentum, small misses become multiple events because the market stops paying for “turnaround optionality.” HELE looks less like a secular compounder and more like a cost-out story; that works only if tariffs and freight stay benign. If input-cost relief stalls or demand softens, margin gains won’t offset weak revenue, which limits rerating potential.

Near term, the catalyst path is all about revisions into the next print cycle and whether management commentary confirms sequential improvement in China, e-commerce, and gross margin. Over 6-18 months, the structural winner is whichever brand can convert retail media and marketplace traffic into repeat purchases without discounting; brands that rely on channel repair alone will fade. The market is likely overpaying for “recovery” narratives and underpricing earnings fragility in lower-growth names.

Key Decisions for Investors

• Long EL / short NUS as a 1-3 month dispersion trade; target 15-20% relative outperformance if EL revisions keep rising and NUS top-line stays negative. Falsify if EL guide cuts or NUS posts positive organic growth.
• Buy EL on pullbacks into earnings; use a 6-12 month horizon for a margin-recovery rerate, but size modestly because China/Sephora/TikTok momentum can reverse quickly if sequential sales flatten.
• Own KVUE as a defensive consumer-health hedge for a 3-6 month risk-off window; best when the market rotates from discretionary to staples. Exit if the stock stops outperforming XLP in a weak tape.
• Avoid chasing HELE strength; if long, treat it as a trade only on evidence of sustained gross-margin expansion, not a secular growth position. Falsify on any tariff re-acceleration or inventory build.
• Short NUS on strength only if the next update shows continued revenue contraction; the risk/reward improves if estimates get revised down again. Cover on any credible evidence of channel stabilization.